We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Antibodies – Multimedia

Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies content piece image
App Note / Case Study

Controlling the Half-Life of Pathological IgG and Therapeutic Antibodies

Various autoimmune diseases (e.g., myasthenia gravis) are mediated by IgG autoantibodies. To address this mechanism of autoimmunity, researchers are exploring the therapeutic use of FcRn inhibitors in an effort to decrease the pathogenesis of IgG and develop new therapies.
Therapeutic Antibodies content piece image
Infographic

Therapeutic Antibodies

In this infographic, we explore the pipeline of therapeutic antibody discovery, development and manufacturing, highlighting key advancements throughout.
New Electron Microscopy Technique Could Shortcut Development of Vaccines and Antibody Therapies content piece image
Video

New Electron Microscopy Technique Could Shortcut Development of Vaccines and Antibody Therapies

Scientists at Scripps Research have devised a method that may be able to shortcut one of the big steps in modern vaccine development.
Mannose Glycans Content Screening for Human-mAb Samples content piece image
App Note / Case Study

Mannose Glycans Content Screening for Human-mAb Samples

Glycosylation refers to the formation of linkages with glycosyl groups, covalently attaching a carbohydrate to another molecule. Antibody glycosylation is critical due to the role carbohydrates play in modulating effector functions which affect safety and efficacy of therapeutic antibodies.
Therapeutic Antibody Engineering: Past, Present and Future content piece image
Listicle

Therapeutic Antibody Engineering: Past, Present and Future

Download this free listicle to learn more about the current scope and future prospects for therapeutic antibody engineering.
Convenient Customization of Your Cation Exchange Analysis content piece image
App Note / Case Study

Convenient Customization of Your Cation Exchange Analysis

Therapeutic monoclonal antibodies (mAbs) are highly heterogeneous molecules due to being composed of a large number of variants. When the variants are present in the pharmaceutical protein, it is possible their biological activity could be altered.
Convenient and Reliable Analysis of Antibody–Drug Conjugates content piece image
App Note / Case Study

Convenient and Reliable Analysis of Antibody–Drug Conjugates

Antibody–drug conjugates (ADCs) are monoclonal antibodies to which a cytotoxic small molecule drug is chemically linked. The structures of ADCs are more complex than their corresponding antibodies.
Preparation of Buffers and Solutions for Therapeutic Antibody Analysis content piece image
App Note / Case Study

Preparation of Buffers and Solutions for Therapeutic Antibody Analysis

Antibodies are subject to instability issues due to chemical and physical instabilities and these effects can change the pharmacokinetics of the antibody. For this reason, produced antibodies must be thoroughly tested before they can be applied for treatment of patients.
Your Guide to Multiple Attribute Methodology (MAM) content piece image
App Note / Case Study

Your Guide to Multiple Attribute Methodology (MAM)

In biotherapeutic process development, evaluating and tracking potential product quality attributes (PQAs) is crucial to ensure quality, safety, and efficacy.
Your Guide to mAb Variants content piece image
App Note / Case Study

Your Guide to mAb Variants

Antibody-based derivatives have received increased attention as therapeutics in biopharmaceutical development because of their unique capacity to engage multiple molecular targets, engage immune effector cells or even penetrate tissues previously inaccessible to conventional mAbs.
Advertisement